IP Library Patent Application 16067193
Patent Application
App. No. 16/067,193

MODULATION OF AFUCOSYLATED SPECIES IN A MONOCLONAL ANTIBODY COMPOSITION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/067,193
Abstract

Alterations in bioreactor cell culture feeding to an extended or continuous feed following an initial period of no feeding reduces the level of high molecular weight, acid charge, and fragment species of monoclonal antibodies expressed in the culture, and enhances the level of afucosylated species of monoclonal antibodies expressed in the culture. Regular fucose infusions following an initial period of no feed media infusion reduces the level of afucosylated species of monoclonal antibodies expressed in the culture. Cell culture manipulation may be used to modulate the level of species of monoclonal antibodies.

Claims (44)

1 . A method for reducing afucosylated species of a monoclonal antibody recombinantly expressed in a bioreactor, comprising

culturing recombinant cells that express the monoclonal antibody in a bioreactor, and

beginning on the first, second, third, fourth, or fifth day of the culture, and continuing every day until the conclusion of the culture, infusing the culture with from about 0.5 g/L to about 5 g/L of fucose such that afucosylated species of the monoclonal antibody expressed by the cells are reduced.

2 . The method according to claim 1 , wherein the monoclonal antibody specifically binds to tumor necrosis factor (TNF) alpha.

3 . The method according to any one of claims 1 to 2 , wherein the recombinant cells comprise mammalian cells.

4 . The method according to any one of claims 1 to 3 , wherein the recombinant cells comprise Chinese Hamster Ovary cells.

5 . The method according to any one of claims 1 to 3 , wherein the recombinant cells comprise HEK293 cells.

6 . The method according to any one of claims 1 to 3 , wherein the recombinant cells comprise Sp2/0 cells.

7 . The method according to any one of claims 1 to 6 , wherein the method comprises infusing the culture with from about 1 g/L to about 5 g/L of fucose.

8 . The method according to any one of claims 1 to 7 , wherein the method comprises infusing the culture with from about 1 g/L to about 4 g/L of fucose.

9 . The method according to any one of claims 1 to 8 , wherein the method comprises infusing the culture with from about 1 g/L to about 3 g/L of fucose.

10 . The method according to any one of claims 1 to 9 , wherein the method comprises infusing the culture with from about 1 g/L to about 2 g/L of fucose.

11 . The method according to any one of claims 1 to 6 , wherein the method comprises infusing the culture with from about 2 g/L to about 4 g/L of fucose.

12 . The method according to any one of claims 1 to 11 , wherein the fucose is infused in a bolus.

13 . The method according to any one of claims 1 to 12 , wherein the culture is a continuous-feed culture in which the culture is further infused with a feed media continuously over a twenty four hour period beginning on the second, third, fourth, or fifth day of the culture, and continuing every day until the conclusion of the culture.

14 . The method according to any one of claims 1 to 12 , wherein the culture is an extended-feed culture in which the culture is further infused with a feed media continuously over a period of from about eighteen to about twenty hours beginning on the second, third, fourth, or fifth day of the culture, and continuing every day until the conclusion of the culture.

15 . The method according to any one of claims 1 to 14 , wherein the afucosylated species comprise the G0 glycan, G1a glycan, G1b glycan, G2 glycan, Man 3 glycan, Man 4 glycan, Man 5 glycan, Man 6 glycan, Man 7 glycan, Man 8 glycan, or Man 9 glycan.

16 . The method according to any one of claims 1 to 15 , wherein the afucosylated species comprises the G0 glycan.

17 . The method according to any one of claims 1 to 16 , wherein the afucosylated species of the monoclonal antibody are reduced to about 10% or less of the total amount of monoclonal antibody expressed by the cells.

18 . The method according to any one of claims 1 to 17 , wherein the afucosylated species of the monoclonal antibody are reduced to from about 2% to about 10% of the total amount of monoclonal antibody expressed by the cells.

19 . The method according to any one of claims 1 to 16 , wherein the afucosylated species of the monoclonal antibody are reduced to about 6% or less of the total amount of monoclonal antibody expressed by the cells.

20 . The method according to any one of claims 1 to 19 , wherein the afucosylated species of the monoclonal antibody are reduced to from about 3% to about 7% of the total amount of monoclonal antibody expressed by the cells.

21 . The method according to any one of claims 1 to 20 , wherein the method comprises culturing recombinant cells that express the monoclonal antibody in a bioreactor for at least twelve days.

22 . A method for reducing afucosylated species of a monoclonal antibody recombinantly expressed in a bioreactor, comprising culturing recombinant cells that express the monoclonal antibody in a bioreactor, beginning on the first, second, third, or fourth day of the culture, and continuing every other day until the conclusion of the culture, infusing the culture with from about 0.5 g/L to about 5 g/L of fucose such that afucosylated species of the monoclonal antibody expressed by the cells are reduced.

23 . The method according to claim 22 , wherein the monoclonal antibody specifically binds to tumor necrosis factor (TNF) alpha.

24 . The method according to any one of claims 22 to 23 , wherein the recombinant cells comprise mammalian cells.

25 . The method according to any one of claims 22 to 24 , wherein the recombinant cells comprise Chinese Hamster Ovary cells.

26 . The method according to any one of claims 22 to 24 , wherein the recombinant cells comprise HEK293 cells.

27 . The method according to any one of claims 22 to 24 , wherein the recombinant cells comprise Sp2/S0 cells.

28 . The method according to any one of claims 22 to 27 , wherein the method comprises infusing the culture with from about 1 g/L to about 5 g/L of fucose.

29 . The method according to any one of claims 22 to 28 , wherein the method comprises infusing the culture with from about 1 g/L to about 4 g/L of fucose.

30 . The method according to any one of claims 22 to 29 , wherein the method comprises infusing the culture with from about 1 g/L to about 3 g/L of fucose.

31 . The method according to any one of claims 22 to 30 , wherein the method comprises infusing the culture with from about 1 g/L to about 2 g/L of fucose.

32 . The method according to any one of claims 22 to 27 , wherein the method comprises infusing the culture with from about 2 g/L to about 4 g/L of fucose.

33 . The method according to any one of claims 22 to 32 , wherein the fucose is infused in a bolus.

34 . The method according to any one of claims 22 to 33 , wherein the culture is a continuous-feed culture in which the culture is further infused with a feed media continuously over a twenty four hour period beginning on the second, third, or fourth day of the culture, and continuing every day until the conclusion of the culture.

35 . The method according to any one of claims 22 to 33 , wherein the culture is an extended-feed culture in which the culture is further infused with a feed media continuously over a period of from about eighteen to about twenty hours beginning on the second, third, or fourth day of the culture, and continuing every day until the conclusion of the culture.

36 . The method according to any one of claims 22 to 35 , wherein the afucosylated species comprise the G0 glycan, G1a glycan, G1b glycan, G2 glycan, Man 3 glycan, Man 4 glycan, Man 5 glycan, Man 6 glycan, Man 7 glycan, Man 8 glycan, or Man 9 glycan.

37 . The method according to any one of claims 22 to 36 , wherein the afucosylated species comprises the G0 glycan.

38 . The method according to any one of claims 22 to 37 , wherein the afucosylated species of the monoclonal antibody are reduced to about 10% or less of the total amount of monoclonal antibody expressed by the cells.

39 . The method according to any one of claims 22 to 38 , wherein the afucosylated species of the monoclonal antibody are reduced to from about 2% to about 10% of the total amount of monoclonal antibody expressed by the cells.

40 . The method according to any one of claims 22 to 37 , wherein the afucosylated species of the monoclonal antibody are reduced to about 6% or less of the total amount of monoclonal antibody expressed by the cells.

41 . The method according to any one of claims 22 to 40 , wherein the afucosylated species of the monoclonal antibody are reduced to from about 2% to about 6% of the total amount of monoclonal antibody expressed by the cells.

42 . The method according to any one of claims 22 to 41 , wherein the method comprises culturing recombinant cells that express the monoclonal antibody in a bioreactor for at least twelve days.

Assignments (2)
CHANGE OF NAME Recorded Dec 13, 2018
From: ONCOBIOLOGICS, INC.
To: OUTLOOK THERAPEUTICS, INC.
Reel/Frame 047826/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2018
From: SANTORO, MARC; JOSE, KEVIN JOHN; MADABHUSHI, SRI; GANGLOFF, SCOTT
To: ONCOBIOLOGICS, INC.
Reel/Frame 046430/0347 →